Fierce Biotech1h
Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
Fierce Biotech6h
Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.
Fierce Biotech10h
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...
Fierce Biotech9h
Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...
Fierce Biotech8h
Siemens AG to acquire lab R&D platform Dotmatics for $5.1B
Siemens AG—and that’s Siemens Siemens, not Siemens Healthineers—is expanding its industrial software business further into ...
Fierce Biotech11h
BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...
Fierce Biotech13h
Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics
Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...